We're excited to announce the launch of our new websites for LumiThera and the Valeda® Light Delivery System! 🌐 www.LumiThera.com 🌐 www.MyValeda.com The new sites reflect our commitment to advancing the treatment of dry age-related macular degeneration (AMD) through innovation, science, and patient-centered care. ✅ Explore the latest clinical data ✅ Learn how Valeda works ✅ Find treatment locations ✅ Access educational resources It’s Time for Patients to See Their Future! #LumiThera #Valeda #DryAMD #Retina #Ophthalmology
LumiThera, Inc.
医疗设备制造业
Poulsbo，Washington 2,198 位关注者
Valeda is FDA Authorized in the US, CE Marked in the EU, and available in select countries in Latin America.
关于我们
LumiThera, Inc. is an ophthalmic medical device company that is Harnessing the Power of Light™ to offer a comprehensive approach for detecting, treating, and monitoring retinal diseases, specifically dry age-related macular degeneration (AMD). LumiThera is the leader in ophthalmic photobiomodulation (PBM) innovation with its flagship product, the Valeda® Light Delivery System. Multiwavelength Valeda treatments are for patients suffering from dry AMD. Valeda is FDA Authorized in the US, CE Marked in the EU, and available in select countries in Latin America. AdaptDx Pro® is a portable dark adaptometer that utilizes AI to deliver a uniform patient experience. AdaptDx Pro is available in the U.S. and Canada. NOVA Vision Testing System is a comprehensive electrophysiology platform that provides objective assessment of the entire pathway for visual and neuro-visual disorders. VEP is available in the U.S. and select countries outside of the U.S. ERG is only available outside of the U.S. For more information on Valeda, visit www.lumithera.com. AdaptDx Pro and NOVA are available through LumiThera Diagnostics, Inc. and Diopsys, Inc., respectively.
- 网站
-
http://lumithera.com
LumiThera, Inc.的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 11-50 人
- 总部
- Poulsbo，Washington
- 类型
- 私人持股
- 领域
- Photobiomodulation、Age Related Macular Degeneration、Ophthalmology、Medical Device、PBM Therapy、Medtech、LLLT、PBM、dry AMD和Retina
地点
-
主要
获取路线
19578 10th Avenue NE, Suite 200
US，Washington，Poulsbo，98370
LumiThera, Inc.员工
动态
-
The LumiThera team is busy preparing for an exciting month of May with multiple events on the calendar. If you would like to schedule a meeting with our sales team, send an email to sales@lumithera.com and we will coordinate a time that works best for you. Looking forward to connecting soon! #Retina #Ophthalmology #Valeda
-
-
Interested in how the Valeda Light Delivery System works? Watch the animation below to see how photobiomodulation treatment with Valeda targets dry AMD at the cellular level. Valeda is the first and only FDA-authorized treatment for Dry AMD to improve vision. #Retina #RetinaHealth #RetinaSpecialist #Ophthalmology #DryAMD #AMD #RetinaCare #RetinalDisease
-
LumiThera aura le plaisir de vous accueillir les 7 et 8 mars 2025 lors du Congrès OPHTA MARS'EYES qui se tiendra au Radisson Blue hotel sur le Vieux Port de Marseille. Venez nombreux nous rencontrer sur notre stand et assister à la session Photobiomodulation à partir de 18H10 le vendredi 7. https://lnkd.in/ekQ3nqhY
-
Heading to 100% Ophthalmology/100% Optical in London? Be sure to visit LumiThera stand E11A to learn about the Valeda Light Delivery System for dry AMD. Our team is looking forward to seeing you there! #100Ophthalmology #retina #DryAMD #ophthalmic
-
-
We're excited to launch the Valeda® Light Delivery System at Hawaiian Eye next week! Stop by LumiThera booth 804 in Retina Row to learn more about the first and only treatment for dry AMD to improve vision. We hope to see you there! #retina #ophthalmology #HawaiianEyeandRetina
-
-
The FDA recently granted authorization to LumiThera, Inc., allowing the company to market its Valeda Light Delivery System. This approval, made under the De Novo authorization pathway, makes Valeda the first FDA-authorized device to treat vision loss in patients with dry AMD. I had the opportunity to speak with LumiThera President and CEO Clark Tedford to learn more about the Valeda technology, its role in the dry AMD market, and the company’s commercialization plans. https://lnkd.in/g28Q9Wxy Eyewire+
-
The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle: https://bit.ly/3ASkVR0
-
Clark Tedford, Phd, LumiThera President and CEO, will be presenting at OIS XIV on Saturday, November 23rd in the Retina Innovation Showcase. Hope to see you there! #OIS #OISXIV #Ophthalmology #Innovation https://ois.net/ois-xiv/
-
The FDA has granted authorization to LumiThera allowijng the company to market its Valeda Light Delivery System. This approval, made under the De Novo authorization pathway, makes Valeda the first FDA-authorized device to treat vision loss in patients with dry AMD: https://bit.ly/4ehfGYL